

DAFTAR PUSTAKA

- Aggarwal, B. B., Kumar, A., Aggarwal, M. S., & Shishodia, S. (2004). Curcumin derived from turmeric (*curcuma longa*): A spice for all seasons. In *Phytotherapeutics in Cancer Chemoprevention*.
- Amir, N. (2015). Skizofrenia. In S. Elvira & G. Hadisukanto (Eds.), *Buku Ajar Psikiatri* (2nd Ed., Pp. 173–198). Badan Penerbit Fakultas Kedokteran Indonesia.
- Barnes, A., & R. R. Donnelley & Sons. (2000). DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS FOURTH EDITION TEXT REVISION. In A.
- Barnes & R. . R. . D. & Sons (Eds.), *library of Congress Cataloging-in-Publication Data Diagnostic* (fourth edi). American Psychiatric Association.
- Bhat, A., Mahalakshmi, A. M., Ray, B., Tuladhar, S., Hediya, T. A., Manthiannem, E., Padamati, J., Chandra, R., & Chidambaram, S. B. (2019). *Benefits of curcumin in brain disorders*. *April*, 1–24. <https://doi.org/10.1002/biof.1533>
- Borovcanin, M. M., Jovanovic, I., Radosavljevic, G., Pantic, J., Janicijevic, S. M., Arsenijevic, N., & Lukic, M. L. (2017). Interleukin-6 in schizophrenia- Is there a therapeutic relevance? *Frontiers in Psychiatry*, 8(NOV), 1–10. <https://doi.org/10.3389/fpsy.2017.00221>
- Chiu, S. S., Woodbury Farina, M., Terpstra, K., Badmaev, V., Cernovsky, Z., Bureau, Y., Jirui, J., Raheb, H., Husn, M., Copen, J., Shad, M., Srivastava, A., Sanchez, V., Williams, M., Khazaeipool, Z., Carriere, A., & Chehade, C. (2017). Targeting Epigenetics Signaling with Curcumin: A Transformative Drug Lead in Treatment of Schizophrenia? *Journal of Clinical Epigenetics*, 03(03). <https://doi.org/10.21767/2472-1158.100066>
- Chase, K. A., Cone, J. J., Rosen, C., & Sharma, R. P. (2016). The value of interleukin 6 as a peripheral diagnostic marker in schizophrenia. *BMC Psychiatry*, 16(1), 1–7. <https://doi.org/10.1186/s12888-016-0866-x>
- Challa, F., Seifu, D., Sileshi, M., Getahun, T., Geto, Z., Kassa, D., Alemayehu, M., Mesfin, M., Fekadu, A., & Woldeamanuel, Y. (2021). Serum level of high sensitive C-reactive protein and IL – 6 markers in patients with treatment-resistant schizophrenia in Ethiopia: a comparative study. *BMC Psychiatry*, 21(1), 4–11. <https://doi.org/10.1186/s12888-021-03443-4>
- A. L., Carrier, M., Tremblay, M. È., & Cruz-Martín, A. (2020). The



Inflamed Brain in Schizophrenia: The Convergence of Genetic and Environmental Risk Factors That Lead to Uncontrolled Neuroinflammation. *Frontiers in Cellular Neuroscience*, 14(August). <https://doi.org/10.3389/fncel.2020.00274>

Cordova, T. J., & Malloy, E. B. (2013). *DSM-5* (T. J. Cordova & E. B. Malloy (eds.); Ed.2). American Psychiatric Association.

Damodharan Dinakaran, V. S. S., & Venkatasubramanian, and G. (2022). Role of Curcumin in the Management of Schizophrenia: A Narrative Review. In Dr. Shahul Ameen (Ed.), *Paper Knowledge . Toward a Media History of Documents*. Official Publication of Indian Psychiatric Society South Zonal Branch.

Depkes RI. (2019). Riset Kesehatan Dasar 2018. Jakarta. Badan Penelitian dan Pengembangan Kesehatan Republik Indonesia.

dr. A.A.A. Agung Kusumawardhani, S. K., Dr. Suryo Dharmono, S. K., Dr. Hervita Diatri, S. K., & Bendahara. (2011). *Konsensus Penatalaksanaan Gangguan Skizofrenia*.

Epstein, K. A., Cullen, K. R., Mueller, B. A., Robinson, P., Lee, S., & Kumra, S. (2014). White matter abnormalities and cognitive impairment in early-onset schizophrenia-spectrum disorders. *Journal of the American Academy of Child and Adolescent Psychiatry*, 53(3), 362-372.e2. <https://doi.org/10.1016/j.jaac.2013.12.007>

Fries, G. R., Stertz, L., Re, G. Z., Badawy, M., Passos, I. C., Barichello, T., Kapczinski, F., & Quevedo, J. (2015). *REVIEW THE ROLE OF INFLAMMATION AND MICROGLIAL ACTIVATION IN THE PATHOPHYSIOLOGY OF PSYCHIATRIC DISORDERS*. May.

<https://doi.org/10.1016/j.neuroscience.2015.05.018>

Goldsmith, D. R., & Rapaport, M. H. (2020). Inflammation and Negative Symptoms of Schizophrenia: Implications for Reward Processing and Motivational Deficits. *Frontiers in Psychiatry*, 11(February), 1–14. <https://doi.org/10.3389/fpsy.2020.00046>

Goldsmith, D. R., Haroon, E., Miller, A. H., Strauss, G. P., Peter, F., & Miller, B. J. (2018). TNF- α and IL-6 are Associated with the Deficit Syndrome and Negative Symptoms in Patients with Chronic Schizophrenia. *Schizophr Res.*, 199, 281–284. <https://doi.org/10.1016/j.schres.2018.02.048>



..., Schneider CD. Alternative therapies: tumeric. *Am J Health-Syst Pharm* 2000; 57(12): 1121-1123.

..., A. (2009). Keefektifan Terapi Remediasi Kognitif Dengan Bantuan

Komputer Terhadap Disfungsi Kognitif Pasien Skizofrenia Kronis di Panti Rehabilitasi Budi Makarti Boyolali. *Surakarta : Program Pendidikan Dokter Spesialis I Program Studi Psikiatri Universitas Sebelas Maret.*

Jayanarayanan S, Smijin S, Peeyush KT, Anju TR, Paulose CS, et al. (2013) NMDA and AMPA receptor mediated excitotoxicity in cerebral cortex of streptozotocin induced diabetic rat: ameliorating effects of curcumin. *Chem Biol Interact* 201: 39-48.

Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., O'Donovan, M., Correll, C. U., Kane, J. M., Van Os, J., & Insel, T. R. (2015). Schizophrenia. *Nature Reviews Disease Primers*, 1(November). <https://doi.org/10.1038/nrdp.2015.67>

Keefe, R. S. E. (2014). The longitudinal course of cognitive impairment in schizophrenia: An examination of data from premorbid through posttreatment phases of illness. *Journal of Clinical Psychiatry*, 75(SUPPL. 2), 8–13. <https://doi.org/10.4088/JCP.13065su1.02>

Keefe, R. S. E., & Harvey, P. D. (2012). Novel Antischizophrenia Treatments - Cognitive Impairment in Schizophrenia. *Handbook of Experimental Pharmacology*, 213, 11–37. <https://doi.org/10.1007/978-3-642-25758-2>

Khandaker, G. M., Cousins, L., Deakin, J., Lennox, B. R., Yolken, R., & Jones, P. B. (2015). Inflammation and immunity in schizophrenia: Implications for pathophysiology and treatment. *The Lancet Psychiatry*, 2(3), 258–270. [https://doi.org/10.1016/S2215-0366\(14\)00122-9](https://doi.org/10.1016/S2215-0366(14)00122-9)

Kirkpatrick, B., & Miller, B. J. (2013). Inflammation and schizophrenia. *Schizophrenia Bulletin*, 39(6), 1174–1179. <https://doi.org/10.1093/schbul/sbt141>

Kummer, K. K., Zeidler, M., Kalpachidou, T., & Kress, M. (2021). Role of IL-6 in the regulation of neuronal development, survival and function. *Cytokine*, 144(4), 82–89. <https://doi.org/10.1016/j.cyto.2021.155582>

Kusumawardhani, A.A.A., Dharmono, S., Diatri, H. (2011). Konsensus Skizofrenia. Perhimpunan Dokter Spesialis Kedokteran Jiwa Indonesia (PDSKJI)

Lamanna-Rama, N., Romero-Miguel, D., Desco, M., & Soto-Montenegro, M. L. (2022). An Update on the Exploratory Use of Curcumin in Neuropsychiatric Disorders. *Antioxidants*, 11(2), 1–27. <https://doi.org/10.3390/antiox11020353>



- Lee, E. E., Hong, S., Martin, A. S., Eyler, L. T., & Jeste, D. V. (2017). Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables. *American Journal of Geriatric Psychiatry*, 25(1), 50–61. <https://doi.org/10.1016/j.jagp.2016.09.009>
- Leucht S, Kane J, Kissling W, Hamann J, Etschel E, Engel R. R. 2005. What does the PANSS mean?. *Schizophrenia Research*, Volume 79, Issues 2– 3, 15 November 2005, Pages 231-238.
- Lumbantoruan, S. D. (2019). *Hubungan Antara Fungsi Kognitif dan Kadar Interleukin-6 (IL-6) pada Orang dengan Skizofreni Suku Batak*. Universitas Sumatera Utara.
- Macciò, A., & Madeddu, C. (2012). Inflammation and ovarian cancer. *Cytokine*, 58(2), 133–147. <https://doi.org/10.1016/j.cyto.2012.01.015>
- Müller, N. (2017). Neuroprogression in Schizophrenia and Psychotic Disorders: The Possible Role of Inflammation. *Modern Trends in Pharmacopsychiatry*, 31, 1–9. <https://doi.org/10.1159/000470802>
- Neelamekam, S., Nurjono, M., & Lee, J. (2014). Regulation of interleukin-6 and leptin in schizophrenia patients: A preliminary analysis. *Clinical Psychopharmacology and Neuroscience*, 12(3), 209–214. <https://doi.org/10.9758/cpn.2014.12.3.209>
- Paul-Samojedny, M., Owczarek, A., Suchanek, R., Palacz, M., Fila-daniłow, A., Borkowska, P., & Kowalski, J. (2013). Association of Interleukin Paranoid Schizophrenia in a Polish Population. *The Journal of Neuropsychiatry and Clinical Neurosciences*, 25, 72–82.
- Patel, K. R., Cherian, J., & Gohil, K. (2014). *Schizophrenia : Overview and Treatment Options*. 39(9), 638–645.
- Riskesdas. (2018). Laporan Provinsi Sulawesi Selatan Riskesdas 2018. In Badan Penelitian Dan Pengembangan Kesehatan (Vol. 110, Nomor 9). <http://ejournal2.litbang.kemkes.go.id/index.php/lpb/article/view/3658>
- Shalehuddin, M., Adi, A. C., M, H. M., & Handajani, R. (2019). Relationship between Duration of Illness and Onset with PANSS and Interleukin-6 in Schizophrenia. *J Brain Res*, 2(2), 109



Sadock BJ; Sadock VA; Ruiz Pedro. (Ed.). (2017). *Kaplan & Sadock's Concise Textbook of Clinical Psychiatry* (4th Editio). Wolters Kluwer.

A., Sarabandi, R., Kianpour, M., & Zakeri, Z. (2016). Elevated serum

interleukin-23 and interleukin-6 levels in schizophrenic patients compared to those in healthy controls. *Shiraz E Medical Journal*, 17(6), 4–8.
<https://doi.org/10.17795/semj38984>

Stahl, S. M. (2016). *Stahl's Essential Psychopharmacology Neuroscientific*. In S. M. Stahl (Ed.), *Stahl's Essential Psychopharmacology Neuroscientific* (Fourth Ed.). Cambridge University Press.

Stahl, S. M. (Ed.). (2021). Psychosis, Schizophrenia, and the Neurotransmitter Networks Dopamine, Serotonin, and Glutamate. In *Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications* (5th ed., pp. 77–158). Cambridge University Press. <https://doi.org/DOI:undefined>

Suat Kucukgoncu, M., Sinan Guloksuz, MD, P., & Cenk Tek, M. (2019). Effects of Curcumin on Cognitive Functioning and Inflammatory State in Schizophrenia A Double-Blind, Placebo-Controlled Pilot Trial. *Journal of Clinical Psychopharmacology*, 39(2), 2017–2019.

Vallée, A. (2022). Neuroinflammation in Schizophrenia: The Key Role of the WNT/ β -Catenin Pathway. *International Journal of Molecular Sciences*, 23(5). <https://doi.org/10.3390/ijms23052810>

World Health Organization. (2022). Mental health ATLAS 2022 state profile. Geneva: World Health Organization. World Health Organization; WHO.

Wynn, J. K., Green, M. F., Helleman, G., Karunaratne, K., Davis, M. C., & Marder, S. R. (2017). The effects of curcumin on brain-derived neurotrophic factor and cognition in schizophrenia: A randomized controlled study. *Schizophrenia Research*, 195, 572–573. <https://doi.org/10.1016/j.schres.2017.09.046>

Zhou, X., Tian, B., & Han, H. Bin. (2021). Serum interleukin-6 in schizophrenia: A system review and meta-analysis. *Cytokine*, 141(January), 155441. <https://doi.org/10.1016/j.cyto.2021.155441>



cht, MD. (2014). Measurements of Response, Remission, and Recovery in Schizophrenia and Examples for Their Clinical Application; *J Clin Psychiatry*

W, Yi Z. A glimpse of gender differences in schizophrenia. *Gen Psychiatr*

[Internet]. 2022 Aug;35(4):e100823. Available from:
<https://gpsych.bmj.com/lookup/doi/10.1136/gpsych-2022-100823>

Orrico-Sánchez A, López-Lacort M, Muñoz-Quiles C, Sanfélix-Gimeno G, Díez-Domingo J. Epidemiology of schizophrenia and its management over 8-years period using real-world data in Spain. *BMC Psychiatry* [Internet]. 2020 Dec 5;20(1):149. Available from: <https://bmcp psychiatry.biomedcentral.com/articles/10.1186/s12888-020-02538-8>
Li R, Ma X, Wang G, Yang J, Wang C. Why sex differences in schizophrenia? *J Transl Neurosci* (Beijing). 2016 Sep;1(1):37–42.

Ochoa S, Usall J, Cobo J, Labad X, Kulkarni J. Gender Differences in Schizophrenia and First-Episode Psychosis: A Comprehensive Literature Review. *Schizophr Res Treatment* [Internet]. 2012;2012:1–9. Available from: <http://www.hindawi.com/journals/schizort/2012/916198/>

Gogtay N, Vyas NS, Testa R, Wood SJ, Pantelis C. Age of Onset of Schizophrenia: Perspectives From Structural Neuroimaging Studies. *Schizophr Bull* [Internet]. 2011 May 1;37(3):504–13. Available from: <https://academic.oup.com/schizophreniabulletin/article-lookup/doi/10.1093/schbul/sbr030>

Weckström T, Elovainio M, Pulkki-Råback L, Suokas K, Komulainen K, Mullola S, et al. School achievement in adolescence and the risk of mental disorders in early adulthood: a Finnish nationwide register study. *Mol Psychiatry* [Internet]. 2023 Jul 2;28(7):3104–10. Available from: <https://www.nature.com/articles/s41380-023-02081-4>

Zhu X, Wen M, He Y, Feng J, Xu X, Liu J. The Relationship Between Level of Education, Cognitive Function and Medication Adherence in Patients with Schizophrenia. *Neuropsychiatr Dis Treat* [Internet]. 2023 Nov; Volume 19:2439–50. Available from: <https://www.dovepress.com/the-relationship-between-level-of-education-cognitive-function-and-med-peer-reviewed-fulltext-article-NDT>

Chafi YK, Amare T, Haile K, Damene W, Tesfaye G, Minichil W. Prevalence and correlates of job loss among schizophrenia outpatients at St. Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia; cross sectional study. De Luca V, editor. *PLoS One* [Internet]. 2020 Dec 28;15(12):e0242352. Available from: <https://dx.plos.org/10.1371/journal.pone.0242352>

Drake RE. Employment and Schizophrenia: Three Innovative Research Approaches. *Schizophr Bull* [Internet]. 2018 Jan 13;44(1):20–1. Available from: <http://academic.oup.com/schizophreniabulletin/article/44/1/20/4743179>

Behere P, Sathyanarayana Rao T, Verma K. Effect of marriage on pre-existing psychoses. *Indian J Psychiatry* [Internet]. 2011;53(4):287. Available from: <https://journals.lww.com/10.4103/0019-5545.91900>

Ponnudurai R, Jayakar J, Sathiya Sekaran B. Assessment of mortality and marital status of schizophrenic patients over a period of 13 years. *Indian J Psychiatry* [Internet]. 2006;48(2):84. Available from: <https://journals.lww.com/10.4103/0019-5545.31595>

Chiu S, Woodbury-farina M, Terpstra K, Badmaev V, Cernovsky Z, Bureau Y, et al. Effect of Curcumin isolated from Turmeric *Curcuma Longa*, the Putative Histone Deacetylase Inhibitor, as added-on strategy to antipsychotics in treating negative symptoms and deficits in Schizophrenia. 2019;40(1):6–15.

Chiu S, Lerner V, Kudkaeva N, Lerner PP, Pashinian A, Bersudsky Y, et al. Curcumin as an Add-on to Antipsychotic Treatment in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study. *Clin Neuropharmacol* [Internet]. 2019 Jul;42(4):117–22.



Available from: <https://journals.lww.com/00002826-201907000-00002>

Dinakaran D, Sreeraj VS, Venkatasubramanian G. Role of Curcumin in the Management of Schizophrenia: A Narrative Review. *Indian J Psychol Med* [Internet]. 2022 Mar 13;44(2):107–13.

Available from: <http://journals.sagepub.com/doi/10.1177/02537176211033331>

Kucukgoncu S, Guloksuz S, Tek C. Effects of Curcumin on Cognitive Functioning and Inflammatory State in Schizophrenia. *J Clin Psychopharmacol* [Internet]. 2019 Mar;39(2):182–4.

Available from: <https://journals.lww.com/00004714-201903000-00022>

Ghandadi M, Sahebkar A. Curcumin: An Effective Inhibitor of Interleukin-6. *Curr Pharm Des* [Internet]. 2017 Mar 27;23(6):921–31. Available from:

<http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1381-6128&volume=23&issue=6&spage=921>

Gorabi AM, Razi B, Aslani S, Abbasifard M, Imani D, Sathyapalan T, et al. Effect of curcumin on proinflammatory cytokines: A meta-analysis of randomized controlled trials. *Cytokine* [Internet]. 2021 Jul;143:155541. Available from:

<https://linkinghub.elsevier.com/retrieve/pii/S1043466621001216>

Peng Y, Ao M, Dong B, Jiang Y, Yu L, Chen Z, et al. Anti-Inflammatory Effects of Curcumin in the Inflammatory Diseases: Status, Limitations and Countermeasures. *Drug Des Devel Ther* [Internet]. 2021 Nov;Volume 15:4503–25. Available from: <https://www.dovepress.com/anti-inflammatory-effects-of-curcumin-in-the-inflammatory-diseases-sta-peer-reviewed-fulltext-article-DDDT>

Zhilyaeva T V., Rukavishnikov G V., Manakova EA, Mazo GE. Serum Interleukin-6 in Schizophrenia: Associations with Clinical and Sociodemographic Characteristics. *Consortium Psychiatricum* [Internet]. 2023 Dec 22;4(4):5–16. Available from: <https://consortium-psy.com/jour/article/view/11067>

Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects. *Biol Psychiatry* [Internet]. 2011 Oct;70(7):663–71. Available from:

<https://linkinghub.elsevier.com/retrieve/pii/S0006322311004045>

Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review. *Biol Psychiatry* [Internet]. 2008 Apr;63(8):801–8. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0006322307009481>

Zhou X, Tian B, Han HB. Serum interleukin-6 in schizophrenia: A system review and meta-analysis. *Cytokine* [Internet]. 2021 May;141:155441. Available from:

<https://linkinghub.elsevier.com/retrieve/pii/S1043466621000211>

Feng Z, Zhang Y, You X, Zhang W, Ma Y, Long Q, et al. Effects of risperidone on blood levels of interleukin-6 in schizophrenia. *Medicine* [Internet]. 2020 Apr;99(15):e19694. Available from: <https://journals.lww.com/10.1097/MD.00000000000019694>

Depkes RI (2009). *Profil Kesehatan Indonesia*. Jakarta: Departemen Republik Indonesia



ab M, Zarghami M, Mazhari S, et al. Nanocurcumin as an add-on to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a double-blind, placebo-controlled study. *J Clin Psychopharmacol*, 2021; 41(7):1000–1007. Available from: https://journals.lww.com/psychopharmacology/abstract/2021/01000/nanocurcumin_as_add-on_to_risperidone_for_treatment_of_negative_symptoms_in_patients_with_chronic_schizophrenia_a_double-blind_placebo-controlled_study.aspx



Optimized using
trial version
www.balesio.com